Find Clinical Trials | Cedars-Sinai

146 results found

Bladder cancer detection, Urology

Early Detection of Bladder Cancer

The purpose of this study is to determine whether an investigational test can assist doctors in evaluating patients at risk of developing bladder cancer with the express purpose of detecting these cancers early, when they ...

Non-Hodgkin's Lymphoma

Alliance, A051902, Phase II, OL, T-cell Lymphomas, CHO(E)P vs CC-486- CHO(E)P vs duvelisib-CHO(E)P

Primary objective: To compare the complete remission (CR) rates by FDG PET/CT using the Lugano 2014 criteria following completion of treatment with duvelisib-CHO(E)P vs CHO(E)P and with CC-486-CHO(E)P vs CHO(E)P in previously untreated peripheral ...

Colon

Roche, WO42758, Intrinsic, Ph 1/1b, OL, mCRC, Inavolisib + Cetuximab or Inavolisib + Bevacizumab

Inavo + Cetux Treatment Arm Primary Efficacy Objectives: To evaluate the efficacy of Inavo + Cetux in PIK3CA-mutated CRC with no detected RAS (KRAS, NRAS) or BRAFV600E mutations Secondary Efficacy Objectives: To evaluate the efficacy of Inavo + Cetux ...

Prostate

NRG, NRG-GU010, Ph 3, Open Label, Prostate, RT vs. RT + ADT vs. RT + ADT + Darolutamide

1.1 Primary Objectives: 1.1.1 De-Intensification Study: To determine whether men with National Comprehensive Cancer Network (NCCN) unfavorable intermediate risk (UIR) prostate cancer and lower Decipher genomic risk (Decipher score < 0.40) treated with RT alone instead of ...

Breast, Colon, Esophagus, Kidney, Lung, Melanoma, Ovary

Shionogi, 2023P2411(aCCeleR8-001), Ph1b/2,Open,Advanced Solid Tumors,S-531011 +/- Pembrolizumab

Primary: -To evaluate the safety and tolerability of S-531011 and to determine the MTD and/or RP2D of S-531011. Secondary: - To evaluate the preliminary antitumor activity of S-531011 per RECIST version 1.1a. - To characterize the PK profile ...